ideasIdea
A social impact bond: investors fund a repurposing trial, payers repay from savings
If a cheap old drug could replace or reduce an expensive cancer treatment, health systems save money. Investors could fund the trial and be repaid from those savings if it works.
Some repurposing questions have direct payer savings attached: a generic that reduces relapse (fewer expensive second-line treatments), replaces a costly supportive drug, or allows de-escalation. The proposal is a development impact bond in which investors fund the trial, an independent evaluator verifies the result and the projected savings, and one or more payers repay investors with a return only if the trial is positive and the intervention is adopted. Outcome-based bonds have funded health interventions in India and the UK; none has funded a cancer trial.
Hypothesis
At least one repurposing trial is financed through a bond within three years, and the structure delivers a positive return to investors in the event of a positive result while costing payers less than 10% of the verified savings.
Rationale
The bond converts a payer's future savings into present trial funding without the payer bearing the risk of a negative result, matching the incentive of the party that benefits with the cost of generating the evidence.
What would test it
Identify three candidate trials with quantifiable payer savings, structure one bond with a national payer and impact investors, and run the trial with pre-registered adjudication.
Maturity
speculative
Who has to act
payer
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.